Narcolepsy Type 1: More Than Just "Feeling Sleepy"
Narcolepsy type 1 (NT1) is a rare, chronic neurological disease driven by a deficiency of orexin in the brain. Patients experience uncontrollable daytime sleepiness, cataplexy (sudden loss of muscle tone triggered by emotions), disrupted nighttime sleep, sleep paralysis, hallucinations, and cognitive symptoms. These symptoms persist 24 hours a day and severely impact work, education, and social interactions.
Oveporexton: Treating the Root Cause, Not Just Symptoms
Takeda recently announced that the New England Journal of Medicine (NEJM) published results from two Phase 3 studies of Oveporexton (brand name ORZEYFUL). Oveporexton is an oral orexin receptor 2 (OX2R) agonist designed to restore orexin signaling and address the underlying cause of NT1. It is the first and only approved orexin agonist to treat the underlying cause of NT1 and is now approved in the U.S., China, and Japan.
Study Designs: FirstLight and RadiantLight
- FirstLight study: 168 participants randomized to twice-daily 2mg, twice-daily 1mg, or placebo.
- RadiantLight study: 105 participants randomized to twice-daily 2mg or placebo.
- Both studies assessed 14 primary and secondary endpoints over 12 weeks. More than 95% of completers enrolled in the ongoing long-term extension study.
Efficacy Results: Comprehensive, Clinically Meaningful Improvements
- Both studies demonstrated consistent, clinically meaningful, and statistically significant improvements versus placebo in wakefulness, sleepiness, cataplexy, disease severity, and quality of life (p-values <0.001) across doses over 12 weeks. Improvements were observed at the earliest assessed timepoint and sustained throughout.
- Median percent reductions in weekly cataplexy rate ranged from 79.0% to 88.8% with oveporexton versus 27.7% to 39.1% with placebo at week 12.
- Oveporexton improved disease severity across all domains of the narcolepsy severity scale (NSS-CT), including EDS, cataplexy, hypnagogic hallucinations, and sleep paralysis. The 2mg dose also improved disrupted nighttime sleep. More than 70% of treated participants reported the lowest severity level (mild) on the NSS-CT.
- Nearly all treated participants (97%) reported improvements in overall narcolepsy symptoms on the Patient Global Impression of Change (PGI-C) scale.
- All dose groups achieved normative thresholds for wakefulness on the Maintenance of Wakefulness Test (MWT ≥20 minutes) and Epworth Sleepiness Scale (ESS ≤10). Most participants reached or exceeded normal thresholds for quality of life outcomes (SF-36 and EQ-5D-5L).
Safety: Generally Well-Tolerated
- The most commonly reported treatment-emergent adverse events were transient insomnia, urinary urgency, urinary frequency, and excessive saliva.
- Most events were mild to moderate, started within two days of treatment, and did not require medical intervention.
- Most insomnia events resolved within one week and did not impair daytime functioning. Approximately half of urinary events resolved by week 12; unresolved events were all mild or moderate.
About Oveporexton (ORZEYFUL)
Oveporexton is an oral orexin receptor 2 (OX2R) agonist that selectively stimulates OX2R to restore signaling and address the underlying orexin deficiency associated with NT1. By activating OX2Rs, oveporexton promotes wakefulness and reduces abnormal REM-sleep-like phenomena, including cataplexy, to address a range of daytime and nighttime symptoms.
Indication: ORZEYFUL is indicated for the treatment of narcolepsy type 1 (narcolepsy with cataplexy) in adult patients.
Important Safety Information: ORZEYFUL is contraindicated in patients taking strong CYP3A inhibitors. In pooled Phase 3 studies, insomnia developed in 60%, 55%, and 1% of patients in the 2mg twice daily, 1mg twice daily, and placebo groups, respectively. Inform patients about the risk of insomnia before initiating treatment. If insomnia persists beyond 7 days and significantly impacts daytime functioning, consult your doctor.
Expert Perspectives
Dr. Emmanuel Mignot, principal investigator, said: "The newly published Phase 3 data reinforce the potential of oveporexton to transform how we approach narcolepsy type 1, shifting from managing individual symptoms to treating the disease itself." Dr. Sarah Sheikh, Head of Neuroscience Therapeutic Area Unit at Takeda, added: "The magnitude of effect seen reinforces the potential of oveporexton to redefine how people feel on treatment."
For people living with narcolepsy, maintaining regular sleep schedules and monitoring sleep quality is essential. The Xiaoshu Health App can sync with Apple Health to track relevant metrics, helping you record daytime sleepiness, nighttime sleep duration, and quality, providing valuable information for your doctor to adjust treatment plans.